Home |  Elder Rights |  Health |  Pension Watch |  Rural Aging |  Armed Conflict |  Aging Watch at the UN  

  SEARCH SUBSCRIBE  
 

Mission  |  Contact Us  |  Internships  |    

 



back

Outcomes: Another Possible Aspirin Benefit for Men


By: John O'Neil
New York Times, March 19, 2002

 

Men over 60 who took aspirin or another anti-inflammatory drug daily were half as likely as those who didn't to be diagnosed with prostate cancer during a six-year Mayo Clinic study.

The gap was even larger among men over 70, according to an article published last week in The Mayo Clinic Proceedings.

Drugs like ibuprofen and naproxen, known as nonsteroidal anti-inflammatories, have been linked to lower levels of colon and breast cancer, said the study's lead researcher, Dr. Rosebud O. Roberts.

Dr. Roberts said many of the men in the study appeared to be taking low doses of aspirin as part of a common regimen for preventing heart disease. She said she suspected that the oldest men showed the greatest benefit either because they were more likely to be taking a lot of anti-inflammatory drugs for conditions like arthritis, or because the drugs have a cumulative effect over decades.

Dr. Roberts said she considered the study's results too preliminary to be a basis of treatment recommendations. And because aspirin and the other drugs all can have significant side effects, she recommended that men considering a daily dose talk with their doctors first.

 


FAIR USE NOTICE: This page contains copyrighted material the use of which has not been specifically authorized by the copyright owner. Global Action on Aging distributes this material without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. We believe this constitutes a fair use of any such copyrighted material as provided for in 17 U.S.C § 107. If you wish to use copyrighted material from this site for purposes of your own that go beyond fair use, you must obtain permission from the copyright owner.